Biogen (BIIB) PT Raised to $415 at BofA Securities After Waterfall Data Despite Modest Treatment Effect
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham raised the price target on Biogen (NASDAQ: BIIB) to $415.00 (from $400.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
